209532-69-4

Basic information

• Product Name: ethyl 6-benzyloxy-4-methyl-3-oxohexanoate
• Synonyms: ethyl 6-benzyloxy-4-methyl-3-oxohexanoate
• CAS NO: 209532-69-4
• Molecular Weight: 278.348
• Mol File: 209532-69-4.mol

Chemical Properties

• CAS DataBase Reference: ethyl 6-benzyloxy-4-methyl-3-oxohexanoate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 6-benzyloxy-4-methyl-3-oxohexanoate(209532-69-4)
• EPA Substance Registry System: ethyl 6-benzyloxy-4-methyl-3-oxohexanoate(209532-69-4)

Safety Data

• Hazardous Substances Data: 209532-69-4(Hazardous Substances Data)

Upstream product

• 31600-42-7 methyl 4-(benzyloxy)butanoate 
• 6148-64-7 ethyl potassium malonate 
• 86227-42-1 methyl 4-benzyloxy-2-methylbutanoate 
• 10385-30-5 4-(benzyloxy)butanoic acid 
• 54555-84-9 benzyl iodoethyl ether 
• 10378-08-2 ethyl 6-(benzyloxy)-3-oxohexanoate 
• 74-88-4 methyl iodide 
• 141-97-9 ethyl acetoacetate 

Downstream Products

• 1427193-62-1 C₂₃H₂₆N₂O₃ 
• 1427193-64-3 C₁₆H₂₀N₂O₃ 
• 1427193-66-5 C₁₆H₁₈N₂O₃ 
• 209532-78-5 2-((E)-6-diphenylphosphoryl-4-hexenyl)-3,4-dimethyl-2-cyclohexenone 
• 209532-72-9 (E)-6-Benzyloxy-3,4-dimethyl-hex-2-enoic acid ethyl ester 
• 209532-73-0 (Z)-6-Benzyloxy-3,4-dimethyl-hex-2-enoic acid ethyl ester 
• 209532-89-8 ((E)-6-Benzyloxy-3,4-dimethyl-hex-2-enyloxy)-tert-butyl-dimethyl-silane 
• 209532-90-1 ((Z)-6-Benzyloxy-3,4-dimethyl-hex-2-enyloxy)-tert-butyl-dimethyl-silane 
• 209532-92-3 (E)-6-Benzyloxy-3,4-dimethyl-hex-2-en-1-ol 
• 209532-93-4 (Z)-6-Benzyloxy-3,4-dimethyl-hex-2-en-1-ol 
• 209532-68-3 2-((E)-6-bromo-3,4-dimethyl-4-hexenyl)-2-cyclohexenone 

Relevant articles and documents

Discovery of novel 7-membered cyclic amide derivatives that inhibit 11beta-hydroxysteroid dehydrogenase type 1

A series of novel 5-trans-hydroxyadamantan-2-yl-5,6,7,8- tetrahydropyrazolo[4,3-c]azepin-4(1H)-ones that inhibit 11beta-hydroxysteroid dehydrogenase type 1 are described. We discovered these 7-membered cyclic amide derivatives by introducing a distinctive linker through pharmacophore analysis of known ligands included in X-ray co-crystal structures. Further optimization using docking studies led to highly potent inhibitors 15b and 27, which furthermore showed the potent efficacy in in vivo studies.